Treatment of Seborrheic Keratosis by High Frequency Focused Ultrasound - An Early Experience with 11 Consecutive Cases
Jacek Calik, Monika Migdal, Tomasz Zawada, Torsten Bove, Jacek Calik, Monika Migdal, Tomasz Zawada, Torsten Bove
Abstract
Purpose: High intensity focused ultrasound operating at 20 MHz has been demonstrated as a safe and efficient treatment modality for a range of dermatological indications. The method is potentially also applicable to removal of seborrheic keratosis.
Patients and methods: A total of 54 seborrheic keratoses in 11 volunteer subjects (8 women and 3 men, average age 51.5 ± 13.2 years) were treated in a single session with a medical 20 MHz high intensity focused ultrasound device developed for dermatological conditions. Handpieces with nominal focal depths of 0.8 mm below the skin surface were used to administer acoustic energy of 0.99-1.2 J/dose. An integrated dermoscope in the handpiece was used to monitor the treatment in real-time. Treatment efficacy and side-effects were assessed directly after treatment and at follow-up 4-15 weeks after treatment.
Results: The treatment showed positive results in 96.3% of the cases. About 68.5% of the cases were classified as complete response and 27.8% of the cases as partial response. Two cases (3.7%) did not respond to treatment and were classified as stable condition. No subjects experienced worsening of their condition, and no treatment received the classification of progressive condition. Side effects were primarily redness in the treatment area due to superficial telangiectasia, mild scarring, and persisting and slow-healing lichen planus-like keratosis. No adverse events were observed.
Conclusion: HIFU is concluded to be a safe and efficient skin treatment for seborrheic keratoses. It has advantages over conventional treatments that can lead to pain during treatment and scarring after healing.
Keywords: HIFU; dermatology; dermoscopy; seborrheic warts; skin tumor; solar lentigo.
Conflict of interest statement
The HIFU device was provided by TOOsonix to the Old Town Clinic for clinical work. Dr Jacek Calik reports non-financial support from Toosonix, during the conduct of the study. Dr Tomasz Zawada and Mr Torsten Bove report a patent EP3589367B1 issued to TOOsonix A/S. The authors report no other conflicts of interest in this work.
© 2022 Calik et al.
Figures
References
- Ellens NPK, Partanen A. Preclinical MRI-guided focused ultrasound: a review of systems and current practices. IEEE Trans Ultrason Ferroelectr Freq Control. 2017;64(1):291–305. doi:10.1109/TUFFC.2016.2609238
- Guillaumier S, Peters M, Arya M, et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol. 2018;74:422–429. doi:10.1016/j.eururo.2018.06.006
- Peek MCL, Wu F. High-intensity focused ultrasound in the treatment of breast tumours. Ecancer. 2018;12:1–10. doi:10.3332/ecancer.2018.794
- Quinn SD, Gedroyc WM. Thermal ablative treatment of uterine fibroids. Int J Hyperthermia. 2015;31(3):272–279. doi:10.3109/02656736.2015.1010608
- Lang BH, Wu ALH. High Intensity Focused Ultrasound (HIFU) ablation of benign thyroid nodules – a systematic review. J Ther Ultrasound. 2017;5:1–9. doi:10.1186/s40349-017-0091-1
- Barile A, Arrigoni F, Zugaro L, et al. Minimally invasive treatments of painful bone lesions: state of the art. Med Oncol. 2017;34(4):53. doi:10.1007/s12032-017-0909-2
- Lamsam L, Johnson E, Connolly ID, Wintermark M, Gephart MH. A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy. Neurosurg Focus. 2018;44(2):1–7. doi:10.3171/2017.11.FOCUS17620
- Farr N, Wang YN, D’Andrea S, et al. Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focused ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. Int J Hyperthermia. 2018;34(3):284‐291. doi:10.1080/02656736.2017.1336675
- Ellens NPK, Hynynen K. Frequency considerations for deep ablation with high-intensity focused ultrasound: a simulation study. Med Phys. 2015;42(8):4896–4910. doi:10.1118/1.4927060
- Ko EJ, Hong JY, Kwon T-R, et al. Efficacy and safety of non-invasive body tightening with high-intensity focused ultrasound (HIFU). Skin Res Technol. 2017;23:558–562. doi:10.1111/srt.12371
- Day D. Microfocused ultrasound for facial rejuvenation: current perspectives. Res Rep Focus Ultrasound. 2014;2:13–17.
- Park JH, Lim SD, Oh SH, Lee JH, Yeo UC. High-intensity focused ultrasound treatment for skin: ex vivo evaluation. Skin Res Technol. 2017;23:384–391. doi:10.1111/srt.12347
- Bove T, Zawada T, Serup J, Jessen A, Poli M. High-frequency (20-MHz) high-intensity focused ultrasound (HIFU) system for dermal intervention: preclinical evaluation in skin equivalents. Skin Res Technol. 2019;25(2):217–228. doi:10.1111/srt.12661
- Soegaard S, Aarup V, Serup J, et al. High frequency (20 MHz) High Intensity Focused Ultrasound (HIFU) system for dermal intervention: a 12 Week Local Tolerance Study in minipigs. Skin Res Technol. 2020;26(2):241–254. doi:10.1111/srt.12786
- Serup J, Bove T, Zawada T, Jessen A, Poli M. High frequency (20 MHz) high-intensity focused ultrasound (HIFU): treatment of actinic keratosis, basal cell carcinoma and Kaposi sarcoma. Skin Res Technol. 2020;26:824–831. doi:10.1111/srt.12883
- Serup J, Bove T, Zawada T, Jessen A, Poli M. High-frequency (20 MHz) high-intensity focused ultrasound: new ablative method for color-independent tattoo removal in 1–3 sessions. An open-label exploratory study. Skin Res Technol. 2020;26:839–850. doi:10.1111/srt.12885
- Bove T, Zawada T, Jessen A, Poli M, Serup J. Removal of common warts by high-intensity focused ultrasound: an introductory observation. Case Rep Dermatol. 2021;13:340–346. doi:10.1159/000515075
- James WD, Berger TG, Elston DM, eds. Andrews Diseases of the Skin. 12th ed. Philadelphia: Elsevier; 2016.
- Elgart GW. Seborrheic keratoses, solar lentigines, and lichenoid keratoses. Dermatoscopic features and correlation to histology and clinical signs. Dermatol Clin. 2001;19(2):347–357. doi:10.1016/S0733-8635(05)70272-2
- Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges. 2008;6(8):664–677. doi:10.1111/j.1610-0387.2008.06788.x
- Mahboob AA, Malvehy J, Braun RP. Atlas of Dermoscopy. 2nd ed. London: Informa Healthcare; 2012.
- Soyer HP, Argenziano G, Hofmann-Wellenhof R, Johr RH, eds. Color Atlas of Melanocytic Lesions of the Skin. Berlin: Springer; 2007.
- Minagawa A. Dermoscopy-pathology relationship in seborrheic keratosis. J Dermatol. 2017;44(5):518–524. doi:10.1111/1346-8138.13657
- Del Roso JQ, Closer A. Look at seborrheic keratoses: patient perspectives, clinical relevance, medical necessity, and implications for management. Clin Aesthet Dermatol. 2017;10(3):16–25.
- Wollina U. Recent advances in managing and understanding seborrheic keratosis. F1000Research. 2019;8(F1000 Faculty Rev):1520. doi:10.12688/f1000research.18983.1
- Sun MD, Halpern AC. Advances in the etiology, detection, and clinical management of seborrheic keratoses. Dermatology. 2021;1–13. doi:10.1159/000517070
- Wolina U. Erbium-YAG laser therapy – analysis of more than 1200 treatments. Glob Dermatol. 2016;3(2):268–272. doi:10.15761/GOD.1000171
Source: PubMed